Targeting UCH-L1 may increase and maintain ERα level by promoting the degradation of EGFR, thereby sensitizing ERα (-) breast cancer cells to the selective ER modulator such as tamoxifen (Figure 7H). The gene discussed is EGFR; the disease is breast carcinoma.